Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne and Receives Priority Review

July 5, 2023

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne

August 7, 2023

PepGen Shares 2023 Q2 Newsletter

July 21, 2023

On July 17, 2023, PepGen shared clinical updates for their Duchenne muscular dystrophy and Myotonic dystrophy type 1 studies and more.

Please click here to view a PDF of their Q2 newsletter.